Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
David Avigan
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07377435CT.gov DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM | — | Recruiting | — | — | — |
NCT06799026CT.gov A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma | — | Recruiting | — | — | — |
NCT05841550CT.gov The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma | — | Recruiting | — | — | — |
NCT03376477CT.gov Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission | — | Terminated | — | — | — |
NCT03782064CT.gov Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma | — | Terminated | — | — | — |
NCT02728102CT.gov Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) | — | Completed | — | — | — |
NCT01827137CT.gov WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | — | Completed | — | — | — |
NCT01245673CT.gov Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma | — | Completed | — | — | — |
NCT01174082CT.gov Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant | — | Terminated | — | — | — |
NCT00834665CT.gov Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT00090493CT.gov Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma | — | Completed | — | — | — |
NCT00952237CT.gov Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF | — | Completed | — | — | — |
NCT00533923CT.gov Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | — | Completed | — | — | — |
NCT00116441CT.gov Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | — | Completed | — | — | — |
NCT00083551CT.gov UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | — | Completed | — | — | — |
NCT00001561CT.gov Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gm-Csf (this asset) | David Avigan | P3 | BB · 64 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Gm-Csf
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P4 | BBB · 74 |
| Melanoma | — | P4 | BBB · 74 |
| Uveal Melanoma | — | P2 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gm-Csf in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gm-csf-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →